MRC1 and pachyonychia congenita: Men with advanced PC who are found to have PVs in the HRD or MMR genes may benefit from targeted therapeutic agents, such as pembrolizumab, platinum therapies, or PARP inhibitors.7–9 Positive men with PC may benefit from identifying increased risk for additional cancers, identifying risks to family members, and understanding the cause of their cancer diagnosis.